Skip to content

Non-invasive Measurement of Gastric Motility

Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04992884
Enrollment
25
Registered
2021-08-05
Start date
2021-05-27
Completion date
2021-10-31
Last updated
2021-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults,Gastric Symptoms,Suspected Gastric Motility Disorders

Brief summary

Clinical evaluation to compare performance of the physiological recordings from the Gastric Alimetry System vs a predicate reference device (Medtronic Polygram NET / Polygraf ID EGG System

Detailed description

A prospective, non-randomised, single centre investigation on patients with suspected motility disorders comprising a simultaneous head-to-head comparison of device performance between the Gastric Alimetry System and the Medtronic Polygram NET / Polygraf ID EGG System.

Interventions

Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.

Sponsors

Greg O'Grady
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 22 years old or older * Able to provide written informed consent * Patients with a suspected motility disorder, meetingRome IVCriteria for functional dyspepsia or chronic nausea and vomiting syndromes or having a diagnosis of gastroparesis as confirmed by a standardized gastric scintigraphy study, including having \>10% gastric meal retention at 4-hours.

Exclusion criteria

* BMI \>35 kg m(2) * Known metabolic, neurogenic or endocrine disorders known to cause gastrointestinal dysmotility e.g. multiple sclerosis, Parkinson's disease, hypothyroidism * Known current gastrointestinal infection (includes H.pylori when being actively treated) * Known current inflammatory bowel disease * Known current gastrointestinal malignancy * Previous gastroduodenal surgery * Open abdominal wounds or abdominal skin not intact (e.g.rash, abrasions, weeping tissues) * Fragile skin evidenced by high susceptibility to skin tears or skin that bruises easily * Regular cannabis use * Allergy to adhesives * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Performance comparison (frequency) between Gastric Alimetry and predicate device90 minutesMean frequency of raw data from predicate device compared with the same measure from the Gastric Alimetry System. Electrode placement is identical and recording is simultaneous.

Secondary

MeasureTime frameDescription
Performance comparison (amplitude) between Gastric Alimetry and predicate device90 minutesMean amplitude of raw data from predicate device (4 electrodes) compared with the same measure from the Gastric Alimetry System (4 electrodes). Electrode placement is identical and recording is simultaneous.
Performance comparison (amplitude) between Gastric Alimetry (4 channels as per Primary Outcome Measure) and Gastric Alimetry (8 highest amplitude electrodes).90 minutesAmplitude of raw data from Gastric Alimetry device (4 electrodes) compared with the same measure from the Gastric Alimetry System (8 electrodes with highest amplitude). Recording is simultaneous.
Safety EndpointFive hoursSafety endpoint: no unanticipated AEs or ADEs, and anticipated AEs and ADEs are acceptable relative to the risk acceptability criteria, as defined by the risk acceptability matrix (RSK-010).
User Needs EndpointFive hoursUser needs validation results meet acceptability criteria.

Countries

New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026